NewAmsterdam Pharma Co N.V. — Form 8-K/A
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
NewAmsterdam Pharma filed an amended 8-K/A on August 14, 2026, covering events from July 16, 2026. Item 5.02 addresses departure of directors/officers and compensatory arrangements. The specific details of departures, appointments, or compensation changes are not disclosed in this filing header; the actual amendment text would be required to identify counterparties, amounts, and specifics of any arrangements.
Why this rating
8-K amendments on officer/director matters are routine corporate housekeeping unless material departure, severance, or equity grant disclosed. No dollar amounts or named individuals provided in header.
Extracted items
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.